- IN₹181.36bn
- IN₹202.94bn
- IN₹31.29bn
Brief: Eris Lifesciences Sept-Quarter Consol Net Profit 1.84 Billion Rupees
Brief: Eris Lifesciences Says Krishnakumar Vaidyanathan Resigns As Executive Director & COO
Brief: Eris Lifesciences Ltd Says June-Quarter Consol Net Profit 1.42 Billion Rupees
Brief: Eris Lifesciences March-Quarter Consol Net Profit 2.82 Billion Rupees
India's Eris Lifesciences falls after Croatia regulator flags issues at Gujarat units
Factbox: Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy
Analysts upbeat on semaglutide opportunity as patent expiry triggers India generics
Brief: Eris Lifesciences Ltd Buys Probiotics Business Of Velbiom Probiotics
Brief: Eris Lifesciences Ltd Launchs Generic Semaglutide Under The Brand ‘Sundae’ In India
India's Eris launches $14 monthly generic Ozempic shot, among cheapest globally
Brief: Eris Lifesciences Launches Generic Semaglutide Under Brand Sundae In India
Brief: Eris Lifesciences Announces Strategic Partnership With Natco Pharma For Semaglutide Launch In India
Brief: Eris Lifesciences Dec-Qtr Consol Net Profit 997.2 Mln Rupees
Brief: Eris Lifesciences Buys 30% Stake Of Unit Swiss Parenterals Ltd
Brief: Eris Lifesciences To Consider Acquiring 30% Stake In Swiss Parenterals
Brief: Eris Lifesciences Posts Sept-Qtr Consol Net Profit 1.2 Billion Rupees
Brief: Eris Lifesciences Sept-Quarter Consol Net Profit 1.2 Billion Rupees
Brief: Eris Receives ANVISA Approval For Sterile Injectable Facility
Brief: Eris Lifesciences June-Qtr Consol Net Profit 1.18 Bln Rupees